Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Kay

Showing results (21-30 of 197) with videos related to

Pageof 20
Sort By:
Molecular Therapy. Oncology|December 24, 2025
Reprogramming AAV tropism with tumor-associated targeting ligandsStephen L Trisno, Mark A Kay
Journal of Virology|June 14, 2003
Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivoAnja Ehrhardt, Hui Xu, Mark A Kay
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 20, 2013
Recombinant AAV as a platform for translating the therapeutic potential of RNA interferenceFlorie Borel, Mark A Kay, Christian Mueller
Methods in Enzymology|January 13, 2005
Adeno-associated virus vectors for short hairpin RNA expressionDirk Grimm, Kusum Pandey, Mark A Kay
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 30, 2007
Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiencyXuan Shen, Terry Storm, Mark A Kay
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 6, 2013
A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitroJiamiao Lu, Feijie Zhang, Mark A Kay
Nature Medicine|June 7, 2008
Wandering eye for RNAiJohn Rossi, Phil Zamore, Mark A Kay
Human Gene Therapy|March 28, 2002
Role of hepatocyte direct hyperplasia in lentivirus-mediated liver transduction in vivoKazuo Ohashi, Frank Park, Mark A Kay
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 9, 2003
The effect of age on hepatic gene transfer with self-inactivating lentiviral vectors in vivoFrank Park, Kazuo Ohashi, Mark A Kay
Nucleic Acid Therapeutics|August 9, 2016
Dieter C. Gruenert, PhD (1949-2016)Petra Disterer, Mark A Kay, Graham C Parker
Pageof 20

Showing results (21-30 of 197) with videos related to

Sort By:
Pageof 20
Molecular Therapy. Oncology|December 24, 2025
Reprogramming AAV tropism with tumor-associated targeting ligandsStephen L Trisno, Mark A Kay
Journal of Virology|June 14, 2003
Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivoAnja Ehrhardt, Hui Xu, Mark A Kay
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 20, 2013
Recombinant AAV as a platform for translating the therapeutic potential of RNA interferenceFlorie Borel, Mark A Kay, Christian Mueller
Methods in Enzymology|January 13, 2005
Adeno-associated virus vectors for short hairpin RNA expressionDirk Grimm, Kusum Pandey, Mark A Kay
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 30, 2007
Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiencyXuan Shen, Terry Storm, Mark A Kay
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 6, 2013
A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitroJiamiao Lu, Feijie Zhang, Mark A Kay
Nature Medicine|June 7, 2008
Wandering eye for RNAiJohn Rossi, Phil Zamore, Mark A Kay
Human Gene Therapy|March 28, 2002
Role of hepatocyte direct hyperplasia in lentivirus-mediated liver transduction in vivoKazuo Ohashi, Frank Park, Mark A Kay
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 9, 2003
The effect of age on hepatic gene transfer with self-inactivating lentiviral vectors in vivoFrank Park, Kazuo Ohashi, Mark A Kay
Nucleic Acid Therapeutics|August 9, 2016
Dieter C. Gruenert, PhD (1949-2016)Petra Disterer, Mark A Kay, Graham C Parker
Pageof 20